Suven Pharmaceuticals Ltd Share Price

Pharmaceuticals - Indian - Bulk Drugs & Formln M/S

NSE: SUVENPHAR Small Cap ISIN: INE03QK01018

As on 22 January 2025 at 15:58 IST

₹1,023.60

-30.10

(-2.86%)

Sell Buy

About Suven Pharmaceuticals Ltd

Suven Pharmaceuticals Ltd is a prominent Indian pharmaceutical company specializing in the development and manufacturing of active pharmaceutical ingredients (APIs) and speciality chemicals. It operates in the pharmaceutical sector, focusing on contract research and manufacturing services (CRAMS) for global pharmaceutical, biotechnology, and chemical companies. The company was established in the year 1989. The headquarters of Suven Pharmaceuticals is located in Hyderabad, Telangana, India. The company’s main products include APIs, intermediates, and specialty chemicals. It also offers a variety of other pharmaceutical services, such as formulation development and clinical supplies manufacturing. Read More...

Over 1 Month

-6.76%

Over 6 Months

24.32%

Over 1 Year

53.42%

Over 3 Years

96.20%

Suven Pharmaceuticals Ltd Summary

Close ₹ 1,023.60

Open ₹ 1,045

High ₹ 1,065.40

Low ₹ 1,011.20

Volume 3,17,481

Net Turnover (in ₹) ₹ 27,18,98,567

52Wk High ₹ 1,360

52Wk Low ₹ 585.20

52Wk High / Low

585.20

1,360

Suven Pharmaceuticals Ltd Fundamentals

Key Financial Data

Market Cap (in ₹Cr) ₹ 26,823.51

EPS (TTM) 9.71

Book Value (BV) 86.66

Div. Yield -

P/E (TTM) 108.71

Price/Book Value 12.18

Delivery % 60.49 %

Face Value 1

Key Ratios

PE Ratio 56.52

PB Ratio 8.38

EV to Sales 16.85

PEG Ratio -1.91

ROA 14.30

ROE 14.31

Debt-Equity 0.04

Net Profit Margin 26.57

Operating Profit Margin 41.10

Suven Pharmaceuticals Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	1,113.26	1,386.69	1,412.60	1,023.96	851.91
Total Expenses	707.59	826.96	786.12	610.02	495.61
Profit Before Tax	405.67	559.73	667.59	467.67	404.51
Profit After Tax	300.28	411.29	453.80	362.34	317
Operating Profit after Depreciation	413.12	572.54	632.71	423.08	376.21

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	669.73	663.33	534.19	441.34	356.89
Total Non Current Assets	990.90	954.70	701.66	909.69	781.17
Total Current Assets	1,263.19	1,011.05	1,127.93	564.79	391.65
TOTAL ASSETS	2,254.09	1,965.74	1,829.59	1,474.48	1,172.81
Total Shareholder's Fund	2,050.66	1,735.18	1,527.18	1,180.80	844.76

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	358.48	457.20	330	382.55	406.92
Net Cash used in Investing Activities	-362.25	-195.01	-136.14	-311.40	-413.45
Net Cash used in Financing Activities	-13.80	-241.95	-156.48	-75.66	7.32

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	1,080.09	1,374.63	1,508.01	1,023.96	851.91
Total Expenses	671.31	795.24	785.56	609.98	494.32
Profit Before Tax	408.77	579.39	722.45	413.98	357.59
Profit After Tax	304.82	432.60	558.10	308.65	270.08
Operating Profit after Depreciation	416.20	592.14	728.68	423.12	376.25

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	523.65	512.03	534.19	441.33	356.89
Total Non Current Assets	1,031.16	1,003.21	695.93	794.13	719.36
Total Current Assets	1,209.55	955.12	1,108.96	564.69	391.53
TOTAL ASSETS	2,240.72	1,958.33	1,804.89	1,358.83	1,110.88
Total Shareholder's Fund	2,055.90	1,749.38	1,520.69	1,065.18	782.83

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	370.65	492.82	269.89	328.84	358.75
Net Cash used in Investing Activities	-381.58	-236.86	-90.36	-257.66	-366.65
Net Cash used in Financing Activities	-13.78	-243.14	-156.41	-75.66	8.57

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	257.72	230.69	252.93	219.82	231.05
Total Expenses	153.71	150.76	179.58	153.76	133.09
Profit Before Tax	99.50	83.09	70.85	65.46	105.41
Profit After Tax	81.98	60.77	53.37	46.75	79.56
Operating Profit after Depreciation	118.13	98.09	90.40	80.40	117.80

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	236.06	222.09	243.52	212.83	224.62
Total Expenses	135.05	139.05	171.38	143.77	127.27
Profit Before Tax	100.68	87.39	71.06	69.51	100.57
Profit After Tax	76.33	65.07	53.43	52.36	74.73
Operating Profit after Depreciation	114.44	100.99	89.01	83.03	111.55

Suven Pharmaceuticals Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 1,021.32

S2 988.93

S3 953.92

Pivot 1,056.33

R1 1,088.72

R2 1,123.73

R3 1,156.12

Moving Average

20 SMA 1,097.10

50 SMA 1,200.55

100 SMA 1,205.26

200 SMA 988.35

Suven Pharmaceuticals Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

No available data

AGM Date: 18 Aug 2022

With reference to the above subject, we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. May 9, 2022, approved the following along with other business matters. e-Annual General Meeting and Date of closure of transfer books a) The 4th e-Annual General Meeting of the members of the Company will be held on Thursday, August 18, 2022 through VC/ OAVM. b) Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Register of Member and Share Transfer Books of the Company will remain closed from August 16, 2022 to August 18, 2022 (both days inclusive) for the purpose of 4th Annual General Meeting of the Company. With reference to the above subject, pursuant to Regulation 34 of the SEBI ((Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Notice convening the 4th AGM of the Members of the Company and the Annual Report for the fiscal 2022 which is simultaneously circulated to the shareholders through electronic mode. The 4th AGM will be held on Thursday, August 18, 2022 at 11:30 a.m. IST through Video Conference (VC) / Other Audio Visual Means (OAVM). The Notice and Annual Report will also be hosted on the Company's website at: https://www.suvenpharm.com/index.php/investors/financial-info/annual-reports. (As Per BSE Announcement dated on 26.07.2022) This is with reference to our earlier letter dated July 26, 2022 regarding the 4th Annual General Meeting (AGM) of the Company held today i.e. August 18, 2022 and the businesses mentioned in the Notice dated May 9, 2022 was transacted. In this regard, please find enclosed the following: 1. Summary of proceedings as required under the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as Annexure - I 2. Voting Results as required under Regulation 44 of the SESI (Listing Obligations and Disclosure Requirements) Regulations 2015 as Annexure- II 3. The Report of Scrutinizer on remote e-voting and voting at AGM (by electronic means) as Annexure- III We request you to take the documents on your record. (As Per BSE Announcement Dated on 18.08.2022)

AGM Date: 15 Dec 2023

Closure of Register of Members for the purpose of 5th Annual General Meeting of the Company Annual Report 2022-23 Notice of the Fifth Annual General Meeting (AGM) and Annual Report 2022-23 (As Per BSE Announcement dated on 22.11.2023) Outcome of 5th Annual General Meeting held on December 15, 2023, Voting results and Report of Scrutinizer. (As per BSE Announcement Dated on 15/12/2023)

AGM Date: 09 Aug 2024

Copy of news paper advertisiment With reference to the above subject, we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. July 12, 2024, approved the following along with other business matters. 1. e-Annual General Meeting (AGM): a) Approved the Notice and Agenda for the 6th Annual General Meeting (AGM) of the Members of the Company scheduled to be held on Friday, the 09th day of August, 2024 at 4.30 p.m. through Video-Conferencing ('VC') or Other Audio Visual Means ('OAVM') b) Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Register of Member and Share Transfer Books of the Company will remain closed from August 07, 2024 to August 09, 2024 (both days inclusive) for the purpose of 6th Annual General Meeting of the Company. We request you to take this document on your records. The Board Meeting commenced at 02:30 p.m. and concluded at 03.45 p.m. Book Closure (As Per BSE Announcement dated on 12.07.2024) 06th Annual General Meeting of the Company will be held on Friday August 09, 2024 at 04.30 PM IST (As Per BSE Announcement Dated on: 16/07/2024) Outcome of the Annual General Meeting 2024 (As Per BSE Announcement Dated on: 09/08/2024)

Suven Pharmaceuticals Ltd Peer Comparison

Company	Price	Market Cap (in ₹ Cr)
Suven Pharmaceuticals Ltd	₹1,055.55	₹26,870.60
Sun Pharmaceuticals Industries Ltd	₹1,761.80	₹4,22,714.84
Divis Laboratories Ltd	₹5,818.40	₹1,54,460.24
Cipla Ltd	₹1,427.30	₹1,15,270.75
Dr Reddys Laboratories Ltd	₹1,288.45	₹1,07,511.36
Torrent Pharmaceuticals Ltd	₹3,157.60	₹1,06,862.73

Suven Pharmaceuticals Ltd News

Suven Pharmaceuticals schedules board meeting

On 12 February 2025

28 Dec 2024, 09:36 am

Suven Pharmaceuticals acquires 56% stake in NJ Bio Inc.

23 Dec 2024, 11:34 am

Suven Pharma to acquire majority stake in US-based NJ Bio

Suven Pharmaceuticals announced that it has signed definitive agreements to acquire a 56% equity stake in NJ Bio, Inc.

07 Dec 2024, 05:20 pm

Suven Pharmaceuticals strengths its ADC offering with acquisition of NJ Bio

07 Dec 2024, 11:24 am

Suven Pharmaceuticals to acquire majority stake in US based NJ Bio

07 Dec 2024, 11:20 am

Suven Pharmaceuticals Ltd Stock Analysis

Annual revenue for Suven Pharmaceuticals Ltd decreased by 21.43% to ₹1,080.09 crore in FY 2024 from ₹1,374.63 crore in FY 2023.
Annual Net Profit for Suven Pharmaceuticals Ltd decreased by 29.54% to ₹304.82 crore in FY 2024 from ₹432.60 crore in FY 2023.
Promoter Shareholding in Suven Pharmaceuticals Ltd remains unchanged by 0.00% in the most recent quarter, from 50.10% in June 2024 to 50.10% in September 2024.
Suven Pharmaceuticals Ltd delivered a 1-year return of 53.42% compared to the Nifty 50, which provided a return of 8.41% as of the last trading session.
Suven Pharmaceuticals Ltd share price moved down by 2.86% from its previous close of INR ₹1,053.70. The latest Suven Pharmaceuticals Ltd share price is INR ₹1,023.60.
Suven Pharmaceuticals Ltd share price today has been at a low of 1,011.20 and a high of 1,065.40. Over the past 52 weeks, the Suven Pharmaceuticals Ltd share price has seen a low of 585.20 and a high of 1,360.

About Suven Pharmaceuticals Ltd

Suven Pharmaceuticals Ltd, founded in 1989, is a prominent Indian pharmaceutical company which is headquartered in Hyderabad, Telangana. The company is a key player in the pharmaceutical industry. It specializes in active pharmaceutical ingredients (APIs) and specialty chemicals. The company also provides contract research and manufacturing services.

Led by Executive Chairperson Annaswamy Vaidheesh, Suven Pharmaceuticals operates with Berhyanda Limited as its majority stakeholder, holding a 50.10% stake. The company caters to pharmaceutical, biotechnology, and chemical clients worldwide. While its registered office is located in Mumbai, Maharashtra, its registrars are based in Hyderabad. They also have a team of managerial promoters who manage the operations of the company. They are

V Prasada Raju
Pankaj Patwari
Shweta Jalan
Matangi Gowrishankar

Suven Pharmaceuticals offers a diverse range of services. It specializes in the development and production of APIs, intermediates, and specialty chemicals. Their service portfolio extends to formulation development, analytical services, and clinical supplies manufacturing. This showcases their comprehensive capabilities in the pharmaceutical sector.

Suven Pharmaceuticals is not the largest player in terms of market capitalization. However, the company has earned a solid reputation through its reliable operations and strong financial stability. It distinguishes itself through an unwavering focus on customer needs and quality excellence in pharmaceutical solutions. Their commitment to innovation and customer satisfaction continues to drive their competitive advantage.

Drawing on decades of pharmaceutical experience, Suven has cemented its position as a dependable industry partner. Their expertise in research and manufacturing enables them to maintain a strong market presence. It also helps the company deliver excellence in pharmaceutical manufacturing and research services.

The Contribution of Suven Pharmaceuticals Limited to the Pharmaceutical Sector

Since its establishment in 1989, Suven Pharmaceuticals Ltd. has emerged as a significant player in the pharmaceutical industry, both in India and globally. The company has built its reputation through expertise in developing and manufacturing active pharmaceutical ingredients, coupled with an unwavering commitment to quality products and services.

A cornerstone of Suven's success lies in its robust research and development initiatives. The company's R&D investments have yielded advanced manufacturing processes and industry-leading products. This focus on innovation has enabled Suven to develop improved APIs and intermediates, which are crucial components in creating effective and safe pharmaceutical products.

Another key area where Suven has made a notable impact is through its Contract Research and Manufacturing Services (CRAMS). The company offers comprehensive solutions to global pharmaceutical and chemical companies. This includes custom synthesis and commercial manufacturing of intermediates and formulations. These CRAMS offerings have proven invaluable to clients, enabling them to bring new drugs to market more efficiently and cost-effectively.

Quality excellence stands as a cornerstone of Suven Pharmaceuticals' contributions to the pharmaceutical sector. The company maintains rigorous quality control measures and strictly adheres to regulatory standards. This ensures its products meet the highest safety and efficacy benchmarks. Their advanced manufacturing facilities, operating under Good Manufacturing Practices (GMP), have helped build a strong reputation and deep trust among clients and stakeholders.

Beyond its pharmaceutical accomplishments, Suven Pharmaceuticals plays a vital role in economic development. The company provides stable and rewarding employment opportunities to thousands of individuals. As a result, it has become a significant contributor to local economies. The employment generated by the company has also positively impacted communities. It has improved the quality of life for many families in the regions where it operates.

Through its diverse contributions, Suven Pharmaceuticals makes a meaningful impact on the pharmaceutical industry. It also positively influences society and the environment. The strong financial performance of Suven Pharmaceuticals highlights its significant impact on the pharmaceutical sector. The company has consistently delivered robust financial results, demonstrating its stability and resilience. Its prudent financial management and strategic investments have contributed to its growth. These efforts have also supported the company's sustained profitability.

The company's impact is also reflected in its commitment to social responsibility. Suven Pharmaceuticals has undertaken various initiatives to support community development and social welfare. These include educational programs and environmental sustainability projects. Suven Pharmaceuticals believes in giving back to society. The company has made significant contributions to improving the quality of life for many people.

Suven Pharmaceuticals enhances its impact on the pharmaceutical sector through strategic partnerships. Its collaborations further amplify its contributions to the industry. The company has formed alliances with various pharmaceutical and chemical companies. These partnerships help enhance its service offerings and expand its reach.

Suven Pharmaceuticals Ltd has made a profound impact on the pharmaceutical sector. The company's focus on innovation, quality, and sustainability has earned it a strong reputation in the industry. The company's contributions extend beyond its products and services to its role in customer satisfaction. Suven Pharmaceuticals has achieved strong financial performance over the years through their relentless dedication towards excellence. Its strategic partnerships have further contributed to its sustained growth and success.